Article in Nature nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Qin Wang *Department of Radiology, The First Affiliated Hospital of USTC, State Key Laboratory of Immune Response and Immunotherapy,Division of Life Sciences and Medicine, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, University of Science and Technology of China, Hefei, China.ORCID http://orcid.org/0000-0002-5947-875X
Cici Zeng *Department of Radiology, The First Affiliated Hospital of USTC, State Key Laboratory of Immune Response and Immunotherapy,Division of Life Sciences and Medicine, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, University of Science and Technology of China, Hefei, China.ORCID http://orcid.org/0009-0004-7230-0499
Ziqi ChenDepartment of Radiology, The First Affiliated Hospital of USTC, State Key Laboratory of Immune Response and Immunotherapy,Division of Life Sciences and Medicine, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, University of Science and Technology of China, Hefei, China.ORCID http://orcid.org/0009-0003-3432-6244
Lei HuDepartment of Radiology, The First Affiliated Hospital of USTC, State Key Laboratory of Immune Response and Immunotherapy,Division of Life Sciences and Medicine, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, University of Science and Technology of China, Hefei, China.
Jiaxiang DouDepartment of Radiology, The First Affiliated Hospital of USTC, State Key Laboratory of Immune Response and Immunotherapy,Division of Life Sciences and Medicine, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, University of Science and Technology of China, Hefei, China.ORCID http://orcid.org/0009-0002-1945-5884
Chengkun YeDepartment of Radiology, The First Affiliated Hospital of USTC, State Key Laboratory of Immune Response and Immunotherapy,Division of Life Sciences and Medicine, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, University of Science and Technology of China, Hefei, China.
Lianbang ZhuDepartment of Radiology, The First Affiliated Hospital of USTC, State Key Laboratory of Immune Response and Immunotherapy,Division of Life Sciences and Medicine, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, University of Science and Technology of China, Hefei, China.ORCID http://orcid.org/0009-0003-3081-2683
Qirui LiangDepartment of Radiology, The First Affiliated Hospital of USTC, State Key Laboratory of Immune Response and Immunotherapy,Division of Life Sciences and Medicine, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, University of Science and Technology of China, Hefei, China.
Huimin PanDepartment of Radiology, The First Affiliated Hospital of USTC, State Key Laboratory of Immune Response and Immunotherapy,Division of Life Sciences and Medicine, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, University of Science and Technology of China, Hefei, China.
Wei JiangDepartment of Radiology, The First Affiliated Hospital of USTC, State Key Laboratory of Immune Response and Immunotherapy,Division of Life Sciences and Medicine, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, University of Science and Technology of China, Hefei, China. jwustc@ustc.edu.cn.ORCID http://orcid.org/0000-0003-0083-0322
Yucai WangDepartment of Radiology, The First Affiliated Hospital of USTC, State Key Laboratory of Immune Response and Immunotherapy,Division of Life Sciences and Medicine, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, University of Science and Technology of China, Hefei, China. yucaiwang@ustc.edu.cn.ORCID http://orcid.org/0000-0001-6046-2934
Funding
National Natural Science Foundation of China (National Science Foundation of China) 52273156National Natural Science Foundation of China (National Science Foundation of China) 52473154National Natural Science Foundation of China (National Science Foundation of China) 52495014National Natural Science Foundation of China (National Science Foundation of China) 52522320
6 · The paper itself
Abstract
Considering that 90% of cancer-related deaths are due to metastasis, treating micrometastases in their infancy is critical. Targeting micrometastases with nanoparticles has shown therapeutic potential, but a limited understanding of the delivery mechanisms has slowed material optimization. Here, using real-time intravital imaging, we discover that nanoparticles can gather around avascular micrometastases through the enhanced permeability of vessels in adjacent non-malignant tissues, defined as the enhanced permeability of adjacent vessels effect. We show that micrometastases have altered mechanical properties and imposed compressive stress on adjacent vessels, activating β1 integrins and subsequent cytoskeletal organization, which leads to the disruption of endothelial integrity and increased vascular permeability. Ultimately, this enhanced-permeability-of-adjacent-vessels-enabled nanoparticle enrichment substantially amplifies the therapeutic outcomes for metastatic interventions. These findings elucidate the mechanisms of nanoparticle delivery to micrometastases, offering promising avenues for nanoparticle-based diagnostics and therapies for metastatic cancer.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Nanoparticles reach metastatic tumours via enhanced permeability of adjacent vessels. · full record | OpenQuestion